Opto-RhoGEFs, an optimized optogenetic toolbox to reversibly control Rho GTPase activity on a global to subcellular scale, enabling precise control over vascular endothelial barrier strength.
Mahlandt EK, Palacios Martinez S, Arts JJG, Tol S, van Buul JD, Goedhart J
Elife. 2023 Jul 14;12:RP84364. doi: 10.7554/eLife.84364.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 176102 | iSH-iRFP670-sspB | Heterodimerization with iLID, phosphatidylinositol 3-kinase derived iSH |
| 176103 | SspB-mCherry-DHPH-ITSN1 | Heterodimerization with iLID, Cdc42 activation |
| 176104 | SspB-mCherry-DHPH-TIAM1 | Heterodimerization with iLID, Rac1 activation |
| 176108 | HaloTag-3xrGBD | Visualization of active Rho |
| 176112 | SSpB-mCherry-p63DH | Heterodimerization with iLID, RhoA activation |
| 176113 | SspB-HaloTag-DHPH-ITSN1 | Heterodimerization with iLID, Cdc42 activation |
| 176114 | SspB-HaloTag-DHPH-TIAM1 | Heterodimerization with iLID, Rac1 activation |
| 176116 | SSpB-HaloTag-p63DH | Heterodimerization with iLID, RhoA activation |
| 176117 | SspB-iRFP-DHPH-ITSN1 | Heterodimerization with iLID, Cdc42 activation |
| 176118 | SspB-iRFP-DHPH-TIAM1 | Heterodimerization with iLID, Rac1 activation |
| 176120 | SSpB-iRFP-p63DH | Heterodimerization with iLID, RhoA activation |
| 176125 | Lck-mTurquoise2-iLID | Plasma membrane localized iLID |
| 176127 | pLV-SspB-HaloTag-TIAM1-DHPH | Heterodimerization with iLID, Rac1 activation |
| 176128 | pLV-SspB-HaloTag-ITSN1-DHPH | Heterodimerization with iLID, Cdc42 activation |
| 176129 | pLV-SspB-HaloTag-p63DH | Heterodimerization with iLID, RhoA activation |
| 176130 | pLV-Lck-FRB-mTurquoise2 | Plasma membrane localized FRB, rapamycin heterodimerization |
| 176134 | pEntr1a-SspB-HaloTag-TIAM1-DHPH | Heterodimerization with iLID, Rac1 activation |
| 176135 | pEntr1a-mcherry-FKBP-TIAM1(DHPH) | Heterodimerization with FRB (rapamycin), Rac1 activation |
| 176138 | pLV-mCherry-FKBP-TIAM1(DHPH) | Heterodimerization with FRB (rapamycin), Rac1 activation |